Objectives: To review the diagnosis and management of four selected psychiatric emergencies in the intensive care unit: agitated delirium, neuroleptic malignant syndrome, serotonin syndrome, and psychiatric medication overdose.
C ritical care physicians frequently care for patients with psychiatric emergencies (see Box 1) . In this article, we review four selected psychiatric emergencies in the intensive care unit (ICU): agitated delirium, neuroleptic malignant syndrome (NMS), serotonin syndrome, and psychiatric medication overdose. Other neuropsychiatric emergencies are discussed elsewhere (1) (2) (3) . Early psychiatric consultation, whenever possible, is indicated to assist in each of these psychiatric emergencies.
DELIRIUM
Delirium has many causes (4) . The patient in the case study (Box 1) was delirious due to serotonin toxicity, though other etiologies were considered. In this section, we will focus on the recognition and management of delirium, which affects up to 75% of critically ill patients (5-9).
Recognition
Delirium is defined as a disturbance of consciousness in which patients have a reduced ability to focus, sustain, or shift attention, along with a change in cognition (e.g., memory deficit, disorientation, or language disturbance) or a perceptual disturbance (e.g., visual hallucinations), that is not better accounted for by dementia (10). The onset of delirium occurs within hours to days, and tends to fluctuate throughout the day (10). Simple and reliable instruments have been validated to screen for delirium in the ICU setting, including the Confusion Assessment Method for the ICU (7) and the Intensive Care Delirium Screening Checklist (6) . Additional instruments like the Richmond Agitation-Sedation Scale (11) can be used to characterize episodes of delirium in terms of motoric subtypes (12, 13): hyperactive (Richmond Agitation-Sedation Scale +1 to +4 during all assessments), hypoactive (Richmond Agitation-Sedation Scale -3 to 0 during all assessments), or mixed (both positive and negative Richmond Agitation-Sedation Scale scores, over time, during a delirium episode).
Risk Factors
In critically ill patients, the etiology of delirium is often multifactorial. The mnemonic "I WATCH DEATH" may be helpful in thinking systematically about risk factors (Table 1) (3, 4, 14) . Other risk factors include immobilization, urinary/fecal retention, and sensory or sleep deprivation (5) . Note that some predisposing factors for delirium are not reversible, e.g., old age and preexisting dementia.
Consequences
Delirium is an independent predictor of mortality (9, 15-20) and long-term cognitive impairment (21-23). Delirium is also associated with self-extubation and removal of catheters (24), longer hospital stays (17, 20, 25) , and higher medical costs (26).
Delirium may also be associated with long-term psychiatric morbidity (27-31). Critical illness and ICU management are inherently stressful (32), especially when patients are unable to mentally process and communicate effectively. Frightening psychotic experiences and related memories may be magnified by the administration of catecholamines, which may cross the blood-brain barrier in sepsis and activate the amygdala to produce traumatic memories (33-37). Studies have demonstrated that approximately 25% of ICU survivors have substantial symptoms of posttraumatic stress (27-30, 38, 39) and/ or depression (27, 31, 40), sometimes lasting for years. Patients who recalled frightening psychotic experiences in the ICU had substantially more of these symptoms (27, 28, 30, 31).
Treatment and Prevention
The management of acute hyperactive delirium involves treating agitation and psychosis and removing/minimizing risk factors. We highlight measures to treat/ prevent delirium beyond standard critical care practice (treating infection, ensuring adequate oxygenation, and managing organ dysfunction and metabolic abnormalities). Note that a prominent hypothesis regarding the pathophysiology of delirium involves deficient cholinergic neurotransmission and excess dopamine neurotransmission (41, 42), and some studies support the use of dopamine blockers (antipsychotics) to prevent delirium (43).
Treat Agitated Delirium and Psychosis. Note that no medications are approved by the Food and Drug Administration to treat delirium. Nevertheless, existing guidelines recommend haloperidol as the medication of choice, based on evidence from case series (44). Advantages of haloperidol include various routes of administration (including the intravenous route for rapid action) and its favorable side-effect profile compared with other antipsychotic drugs commonly used in the ICU setting (44). Although haloperidol can cause dosedependent electrocardiogram QT interval prolongation, it appears to cause less QT prolongation than other antipsychotics (45). Notably, extrapyramidal symptoms are less common with intravenous haloperidol administration than with oral or intramuscular administration (46, 47). Based on small trials in critically ill patients with delirium (including various motoric subtypes), atypical antipsychotics may be as effective as enteral haloperidol (48-52). To our knowledge, only two studies of antipsychotics for delirium in the ICU have employed a placebo control group (50, 51). First, in a three-arm randomized, blinded feasibility study, neither low-dose haloperidol nor ziprasidone (both administered enterally) significantly outperformed placebo in reducing the time patients spent delirious or comatose (50); however, a larger trial with these same medications is evaluating this question more definitively (ClinicalTrials. gov identifier NCT01211522). Second, in a placebo-controlled trial, quetiapine 50-200 mg every 12 hrs reduced the durations of both delirium and agitation (51); in the trial, intravenous haloperidol was administered, as needed, to patients in both treatment groups-patients in the quetiapine group required fewer days of haloperidol. Beyond the management of agitation, antipsychotics may be used to reduce frightening psychotic symptoms in delirious patients (including those with hypoactive delirium); in order to detect these symptoms, clinicians should have a high index of suspicion and question the patient directly, when possible.
Dexmedetomidine may also have a role in the treatment of agitation. Existing studies have particularly focused on agitation in the setting of ventilator weaning. In one open-label pilot study, 20 patients who could not be successfully weaned because of agitated delirium were randomized to continuous infusions of haloperidol (0.5-2 mg/hr) or dexmedetomidine (0.2-0.7 μg/kg/hr) (53). Dexmedetomidine was associated with a significantly shorter median time A 50-yr-old man with a history of bipolar disorder, viral hepatitis, and suicide attempts via overdose was brought to his local emergency room by his wife because he was confused (unable to remember his wife's name), febrile, perspiring excessively, and "stiff." The day prior he had been tremulous and anxious. Upon arrival, he was febrile with increased white blood cell count, transaminases, ammonia, and creatine phosphokinase. No source of infection was identified, and a toxicology screen for common illicit drugs was negative.
The patient was admitted to the intensive care unit (ICU), hydrated vigorously, intubated, and sedated with propofol and haloperidol. His home psychiatric medications (olanzapine, bupropion, and fluoxetine) were held. Brain imaging and cerebrospinal fluid findings were unremarkable. Given clinical worsening, with increased muscle tone, his physicians wondered whether the patient may have neuroleptic malignant syndrome. They administered a single dose of dantrolene, which appeared helpful. The patient was extubated and discharged home after several days. However, he was readmitted to the ICU a week later with a recurrence of his symptoms, and he was transferred to a tertiary medical center.
Upon transfer, he was hyperactive, tremulous, diaphoretic, febrile, and unable to communicate. He exhibited both hyperreflexia and myoclonus. Upon detailed review of his medical records, it became evident that the patient's fluoxetine dose had been doubled shortly before his initial ICU admission (the patient had had worsening depressive symptoms). In between admissions, he had resumed taking fluoxetine. Given his history and acute symptoms, the patient's acute neuropsychiatric state was reformulated as serotonin syndrome. His physicians administered cyproheptadine, and most of his symptoms resolved within 24 hrs. After resolution of his delirium and urinary retention on a general medical ward, he was transferred to the inpatient psychiatric service for treatment of recurrent depression.
to extubation (20 vs. 42 hrs, p = .016), as well as a significantly shorter ICU length of stay after study drug commencement (1.5 vs. 6.5 days, p = .004) (53). In another open-label, uncontrolled study of 28 patients with agitation during weaning, dexmedetomidine infusion (0.4-1.0 μg/ kg/hr) was associated with rapid resolution of agitation (within 6 hrs of infusion commencement) and successful extubation after a median of 70 (interquartile range 28-96) hrs (54). Unfortunately, dexmedetomidine is substantially more expensive than haloperidol, though higher drug costs may be offset by shorter ICU lengths of stay.
Note that administration of medications is not the only intervention that can help agitated delirium. Calm verbal reassurance and reorientation by staff and/or family is also important (4) .
Manage Sedation Carefully. Medications that increase γ-amino butyric acid neurotransmission (i.e., benzodiazepines and propofol) are common and important modifiable risk factors for delirium (55-58) and coma (59-62). As needed, bolus dosing and interruption of continuous infusions of sedatives reduce delirium and the duration of mechanical ventilation (59, 63-66) without increasing post-ICU psychological distress (67, 68) . Continuous infusions of dexmedetomidine, a non-γ-amino butyric acid-ergic sedative, appear less deliriogenic than benzodiazepine infusions (56, 58). Morphine-only sedation also appears to reduce ICU length of stay (69) . Note that, if alcohol or other γ-amino butyric acid-ergic sedative withdrawal is suspected, patients are generally given benzodiazepines more liberally (4) .
Minimize Anticholinergics. Anticholinergic drugs are highly deliriogenic (70) (71) (72) (73) and should be withheld, when possible, in ICU patients. Of >100 medications commonly prescribed in the elderly (74), those with the most potent anticholinergic properties included dicyclomine, L-hyoscyamine, tolterodine, doxepin, amitriptyline, thioridazine, and clozapine. Those with the next most potent anticholinergic properties included diphenhydramine, oxybutynin, nortriptyline, paroxetine, olanzapine, and chlorpromazine (74) . Currently, cholinesterase inhibitors are not indicated for the prevention or treatment of delirium, given negative clinical trial results and potential harm in ICU patients (75) (76) (77) (78) .
Manage Pain. Inadequately treated pain disrupts sleep and is a risk factor for delirium (79, 80) . On the other hand, it is important not to use excessive doses of opioids. Some opioids may be relatively less deliriogenic (e.g., morphine) (57, 81), whereas others appear particularly deliriogenic (e.g., meperidine and tramadol) (81) (82) (83) (84) (85) (86) .
Promote a More Normal Sleep-Wake Cycle. Disrupted sleep can be both a risk factor for delirium and a manifestation of delirium. Several interventions may be helpful (87) . First, promote a quiet environment at night by reducing loud conversations, televisions, unnecessary alarms, and overhead pages (88) (89) (90) . ICU noise levels often exceed 80 decibels, the threshold associated with sleep disruption (91) (92) (93) (94) . Second, group together disruptive, but necessary, patient care activities, like clinical assessments, medication administration, wound care, bathing, phlebotomy, transportation, and radiographs (90, 93, 95, 96) . Third, minimize sedative agents known to disrupt sleep (e.g., benzodiazepines), and consider alternate methods to address insomnia (i.e., including nondrug measures) (97) . Fourth, keep patient rooms dark at night and bright (with daylight) during the daytime (4) .
Early Physical Rehabilitation. Providing early physical and occupational therapy in the ICU reduced the duration of delirium and improved physical function in a randomized trial (98) . Similarly, an ICU quality improvement project that reduced sedation and facilitated rehabilitation was associated with an increased proportion of ICU days without delirium or coma (99) . Conversely, immobility and physical restraints may increase the risk of delirium (100) .
Reduce Sensory Deprivation and Orient Patients. Poor visual acuity and hearing impairment are risk factors for delirium (101, 102) . Providing eyeglasses and/or hearing aids were part of a multifaceted strategy that reduced delirium in older hospitalized patients (103) . Clocks and calendars in patients' rooms (104) and verbal orientation by staff and/or family members (4) may also be helpful.
NEUROLEPTIC MALIGNANT SYNDROME
The features of NMS, serotonin syndrome (SS), and other toxidromes overlap substantially (105, 106) . Table 2 illustrates shared and unique features of NMS and SS. The DSM-IV criteria for NMS include severe muscle rigidity, elevated temperature, and other related findings (e.g., diaphoresis, incontinence, decreased level of consciousness, mutism, elevated or labile blood pressure, elevated creatine phosphokinase) developing in association with the use of neuroleptic (i.e., antipsychotic) medication (10). Box 2 lists common antipsychotic medications, as well as other dopamine-blocking drugs (e.g., antinausea medications) that can contribute to NMS. Other adverse drug reactions associated with hyperthermia that should be considered in the differential diagnosis of NMS and SS include adrenergic or anticholinergic toxicity, or uncoupling of oxidative phosphorylation-none of which should be associated with rigidity; malignant hyperthermia (postanesthesia); and baclofen withdrawal (with muscle spasm) (106) .
NMS may be increasingly relevant to ICU physicians, given the frequent administration of antipsychotics to critically ill patients for agitated delirium (44, 107). Importantly, several NMS risk factors are common in ICU patients: agitation and use of typical antipsychotics (e.g., haloperidol), often in parenteral form, in higher doses (e.g., 20 mg of haloperidol daily), and in patients who are neuroleptic-naïve (108-111).
Treatment
The correct diagnosis is vital. In particular, the dopamine agonist bromocriptine, given for presumed NMS, can cause or worsen SS. Also, antipsychotics for hyperactive delirium or presumed SS can worsen/prolong NMS (112, 113) . No medications are approved by the Food and Drug Administration for the treatment of NMS; recommendations for treatment have been drawn from case series (113) . Note that consultation with local poison control centers can be helpful in the management of both NMS and SS (listed at http://www.aapcc.org/dnn/default.aspx).
Discontinue All Dopamine Blockers. It is important to note that antipsychotics are not the only drugs that block dopamine neurotransmission. As shown in Box 2, metoclopramide, prochlorperazine, and promethazine are also dopamine blockers (113) .
Provide Supportive Care. Supportive care is the mainstay of treatment for NMS (112, 113) . This includes vigorous hydration, attention to electrolyte abnormalities, external cooling for extreme hyperthermia, and managing complications (cardiorespiratory and renal failure, aspiration, and coagulopathies) (112, 113) .
Consider Benzodiazepines for Milder
Cases. Benzodiazepines (e.g., lorazepam 1-2 mg intravenously every 4-6 hrs) may ameliorate symptoms in milder cases of NMS, particularly catatonic symptoms like mutism and immobility (113, 114) .
Consider Dopaminergic Agents. Bromocriptine (starting at 2.5 mg bid-tid, up to 45 mg/day), amantadine (200-400 mg/day in divided doses), and other enterally administered dopaminergic agents may reverse parkinsonian symptoms (e.g., rigidity) (113), speed recovery, and reduce mortality (115, 116) . Note that bromocriptine can precipitate psychosis, hypotension, and vomiting, in which case alternative medications should be considered. Bromocriptine should be continued for 10 days after resolution of NMS, as patients can have a recurrence if it is discontinued prematurely (113) .
Consider Dantrolene. The skeletal muscle relaxant dantrolene appears to reduce symptoms, speed recovery, and reduce mortality in patients with NMS who have extreme hyperthermia and rigidity (113, 115, 116) . Note that benzodiazepines or dopamine agonists can be administered with dantrolene, but not calcium channel blockers given the risk of cardiovascular collapse (113) . Patients can be administered 1.0-2.5 mg/kg intravenously, then 1 mg/kg every 6 hrs if hyperthermia and/or rigidity reduces after the first dose. Side effects can include respiratory and hepatic impairment. If the patient has a good response, dantrolene can be tapered and switched to an oral preparation after the first few days. Dantrolene should be continued for 10 days after resolution of NMS, as patients can have a recurrence if it is withdrawn prematurely (113) .
Consider Electroconvulsive Therapy. Electroconvulsive therapy should be considered if supportive care and pharmacotherapy are ineffective after 2 days (113, 117) . Electroconvulsive therapy has been effective in pharmacotherapy-resistant cases (117) . 
SEROTONIN SYNDROME

Recognition
SS is characterized by clonus, agitation, diaphoresis, increased muscle tone, elevated temperature, hyperreflexia, and tremor (105, 118, 120) . Other symptoms can include confusion, shivering, dilated pupils, hyperactive bowel sounds, tachycardia, and hypertension (105, 118) . The most sensitive and specific sign of SS is clonus (121) , as highlighted in the Hunter Serotonin Toxicity Criteria (Box 4). Unfortunately, many physicians lack knowledge regarding SS, so the diagnosis is often delayed (122) . Thus, it is important for clinicians to be aware of the signs and consider the diagnosis in patients who have been treated with serotonergic drugs.
Treatment
Discontinue Serotonergic Drugs. Some patients' symptoms will resolve within a day of discontinuing serotonergic medications with supportive therapy. However, it is important to note that fluoxetine and its active metabolite have very long half-lives, producing a prolonged syndrome.
Provide Supportive Therapy. Supportive care for SS involves administration of intravenous fluids and normalization of vital signs. Avoid longer-acting Other dopamine blockers: metoclopramide, prochlorperazine, promethazine β-blockers, which can lead to hypotension in patients with autonomic instability (105) . Control Agitation. Agitation in SS can be fairly severe, and sedation with benzodiazepines may be necessary. Benzodiazepines improve survival in animal models of SS, perhaps through a blunting of the hyperadrenergic state (123) . Caution is required with the use of physical restraints because persistent struggling against restraints could contribute to worsening lactic acidosis, hyperthermia, and mortality (105, 124) .
Consider Serotonin 2A Antagonists. Although no medication is approved by the Food and Drug Administration for the treatment of SS, results from case series suggest that patients with moderate-tosevere SS (e.g., tachycardia, hypertension, and hyperthermia) should receive serotonin 2A receptor antagonists (105) . Cyproheptadine, an antihistamine, is a potent blocker of this receptor at higher doses (12-32 mg in a 24-hr period) (105, 119, 125) . A starting dose of 12 mg can be crushed and administered via a nasogastric tube, followed by 2 mg every 2 hrs if symptoms continue, and 4-8 mg q6 hrs for maintenance dosing. In cases in which NMS has been ruled out clinically, the antipsychotic chlorpromazine (e.g., 50-100 mg intramuscular) and atypical antipsychotics may also be considered as alternative serotonin 2A antagonists. If activated charcoal has been administered recently, parenteral chlorpromazine may be necessary, as cyproheptadine is not available in parenteral form (120) .
Control Autonomic Instability. Patients with hypotension from monoamine oxidase inhibitor interactions with other serotonergic drugs can be treated with low doses of direct-acting sympathetic amines like norepinephrine, phenylephrine, or epinephrine; dopamine should be avoided because of the risk of an exaggerated hemodynamic response (105) . In patients who develop hypertension and tachycardia, short-acting agents such as nitroprusside or esmolol are preferred (105) .
Control Hyperthermia. Temperature elevations in serotonin syndrome can be severe (>41°C). Antipyretics are not helpful. Patients with high temperatures should be intubated for airway protection to allow deep sedation and neuromuscular blockade with a nondepolarizing agent (105) , and active cooling measures should be instituted.
Avoid Bromocriptine and Dantrolene. Bromocriptine can precipitate SS (126); a patient treated with bromocriptine and dantrolene died with signs of worsening SS (127) . Notably, dantrolene did not improve survival in an animal model of SS (123) .
MEDICATION OVERDOSE
Patients with psychiatric illnesses are often treated in ICUs after intentional overdoses (128, 129) , and ICU physicians must make decisions regarding psychiatric medications, ideally in collaboration with psychiatric consultants. In this section, we outline two principles for patient management.
First, it is often unnecessary to restart psychiatric medications in the critical care setting, i.e., they can be held pending a psychiatric consultation. However, holding certain psychiatric medications could result in withdrawal. For example, if a patient has been taking a regular dose of a benzodiazepine, it may be necessary to continue it in order to prevent withdrawal symptoms. However, the dose may need to be adjusted based on the clinical state of the patient (e.g., a lower dose if the patient is obtunded or has organ dysfunction affecting drug clearance). Similarly, abruptly stopping serotonin reuptake inhibitors can lead to a distressing withdrawal syndrome that should be avoided by tapering the medicine gradually (130, 131) . Second, it is important to communicate with the physician who prescribed the medication on which the patient overdosed. For example, after a patient has overdosed with a tricyclic antidepressant, a psychiatrist may discontinue this medication and prescribe a medication from an alternative antidepressant class.
CONCLUSIONS
Intensivists often care for patients with psychiatric emergencies. Agitated delirium should be managed with an antipsychotic and, possibly, dexmedetomidine, as well as measures to minimize delirium itself. NMS should be treated by discontinuing dopamine blockers and possibly administering medications (benzodiazepines, dopamine agonists, and/or dantrolene) or electroconvulsive therapy. Serotonin syndrome should be treated by discontinuing all serotonergic agents, controlling agitation with benzodiazepines, and possibly administering serotonin 2A antagonists. It is often unnecessary to restart psychiatric medications upon which a patient has overdosed in the ICU, though withdrawal syndromes should be prevented, and communication with outpatient prescribers is vital. ium in mechanically ventilated patients:
Validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU 
